Default company panoramic image
Kalionlogolarge

Kalion, Inc.

Use patented microbial pathway to produce pharma and nutraceutical ingredients. Start with highest value product, glucaric acid, then address high $$ polymers.

  • Stage Product In Development
  • Industry Chemicals and Chemical Products
  • Location Milton, MA, USA
  • Currency USD
  • Founded September 2010
  • Employees 2
  • Incorporation Type C-corp
  • Website kalioninc.com

Company Summary

Kalion is an early stage industrial biotech company that will transform the traditional chemical industry by providing low-cost access to glucaric acid using traditional, green, fermentation technology. Glucaric acid was identified as a “Top Value Added Chemicals from Biomass” and multi-billion dollar markets for use glucaric are limited by cost (2004 DOE report). Our technology allows for an order of magnitude improvement in cost to only $1/lb.

Team

  • Default avatar
    Neal Connors
    CTO

    Neal is a contributing author on numerous peer-reviewed papers, book chapters, patents, and conference abstracts. He is a past president of the Society for Industrial Microbiology. He received his BS in Biology from Norwich University in 1984 and his PhD in Microbiology from Ohio State University in 1991. From 1991 to 2008, he was in the Bioprocess R&D department of Merck & Co., Inc. .

  • Default avatar
    Alan Watson
    VP Development

    Dr. Watson has almost thirty years of experience in the pharmaceutical and biotechnology industries. Dr Watson received his B.Sc. (Hons) from the University of N.S.W. in Sydney, Australia, his Ph.D. in Chemistry from the Australian National University and carried out postdoctoral research at Harvard University. He also obtained an M.B.A. from Northeastern University. he negotiated the sale of SmartCells to Merck & Co. for $500M

  • Default avatar
    Kristala Prather
    Advisor

    Theodore T. Miller Career Development Associate Professor of Chemical Engineering at MIT. She obtained a Bachelor of Science degree in chemical engineering from MIT in 1994, and a Ph.D. degree from the University of California, Berkeley, in 1999. At Berkeley, she worked under the supervision of Prof. Jay D. Keasling. Prof. Prather joined the faculty of MIT after 4 years in BioProcess Research and Development at Merck Research Labs (Rahway, NJ).

  • Default avatar
    Darcy Prather
    President

    Mr. Prather has spent a couple of decades developing new business from emerging technologies. Mr. Prather received two S.B.’s from the Massachusetts Institute of Technology in Electrical Engineering; and Science, Technology and Society. He received an M.A. in Philosophy, Politics and Economics from Oxford University which he attended on a Rhodes Scholarship. Mr. Prather worked for McKinsey & Co., NiaOnline as CTO and Beta Data as VP Strategy.

Advisors

  • Default avatar
    WilmerHale
    Lawyer
    Unconfirmed
    Default avatar
    Dennis & Associates
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Cherrystone Angel Group - Middle of Raise
    Unconfirmed
    Default avatar
    James Prather - Conv. Debt
    Unconfirmed